- No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
NNOX
NASDAQ
Week ended 24 Jul 2026
Weekly Investor Report
Nano X Imaging Ltd · Healthcare · Medical Devices
Latest close
0.90 USD
-20.0%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is -57.6% below the Trend Line and sits at 3.6% of its 52-week range. The latest completed week returned -20.0%, after a -17.8% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 52/100 conviction, while the latest news-sentiment score is 32/100. Near-term considerations: volume confirmation is below normal; earnings are due in 13d.
Setup score
9
out of 100
Latest Close
0.90 USD
24 Jul 2026
1W Return
-20.0%
latest completed week
4W Return
-17.8%
short-term follow-through
12W Return
-48.2%
quarterly tape
Trend Breadth
0.0%
0 of 52 weeks active
Volume Ratio
0.5x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-20.0%
Latest completed week; four-week move -17.8%.
Indicator stack
0/4
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 43.59%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
Options pressure
Volatility
52/100 conviction; expected move 31.0%.
News sentiment
32/100
54 relevant articles in the latest sentiment read.
Event risk
13d
Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -57.6% below the Trend Line and sits at 3.6% of its 52-week range. The latest completed week returned -20.0%, after a -17.8% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.5x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
30 Jan
6 Feb
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.0112-week average 0.02
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure1/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.01Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -17.8% over four weeks, -48.2% over 12 weeks, and -82.8% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-1.13Latest activity-pressure read.
Pressure change-322.1%Four-week change in activity pressure.
Leadership-71.70Latest relative-leadership reading.
RS change-1.7%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is neither clearly cheap nor expensive.
Factor week 26 Jul 2026
Financial statements through 31 Dec 2025
Field coverage 82%
Model confidence 78%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength17/100Blend of value, momentum, and quality. Underlying universe rank 84; rank 1 is best.
Value66/100Relative valuation strength. Underlying universe rank 35; rank 1 is best.
Quality2/100Profitability and accounting quality. Underlying universe rank 99; rank 1 is best.
Momentum2/100Medium-term price momentum. Underlying universe rank 99; rank 1 is best.
Growth81/100Revenue and earnings growth. Underlying universe rank 20; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 4.3x Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -152.7% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- -87.7% Gross profit retained from each unit of revenue.
- Operating margin
- -416.3% Operating profit retained from revenue.
- Free-cash-flow margin
- -275.2% Free cash flow generated from revenue.
- Return on invested capital
- -50.3% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 25.7% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 2/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -34.0% Net share repurchases relative to market value.
- Shareholder yield
- -34.0% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 0.7x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Options positioningVolatility
NNOX shows volatility options pressure with a 52/100 conviction score, put-call volume ratio of 0.06, expected move of 31.0%, and Sharemaestro trend signal inactive.
Conviction52/100
Expected move31.0%
Put/call volume0.06
Insider activity-
No recent insider transactions are stored for this company.
News sentiment32/100
Weighted news tone is negative across 54 relevant articles.
3 positive · 24 neutral · 27 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings13dNext report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
Options expected move31.0%Nearest-chain priced movement where available.
52-week drawdown-82.9%Distance below the 52-week high.
13-week volatility13.5%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
30 Jan
27 Feb
27 Mar
24 Apr
22 May
19 Jun
24 Jul
Weeks higher9 of 2616 weeks finished lower.
Best week+25.6%Week of 17 Apr.
Worst week-39.1%Week of 24 Apr.
Latest week-20.0%Week of 24 Jul.
Shape of recent returns
Strong gains8
Modest gains1
Flat weeks1
Modest losses3
Sharp losses13
Recent vol13.5%13-week weekly-return volatility.
Base vol13.1%52-week weekly-return volatility.
Up/down split20/31Count of positive and negative weeks in the 52-week window.
Average skew8.8% / -9.8%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank- / 100
Group average1.3%
Trend breadth51.0%
Trend51.0%active weekly trend signals
MD75.0%positive activity pressure
RS48.0%positive relative leadership
Four-week leaders
IndustryUS Medical Devices
4-week rank90 / 100
Group average-3.4%
Trend breadth34.0%
Trend34.0%active weekly trend signals
MD65.0%positive activity pressure
RS20.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape9/100
Trend, activity pressure, participation, and risk combine to a 9/100 tape read.
Indicator analysis10/100Latest 12-week confirmation: trend 0/12, activity pressure 1/12, relative leadership 0/12.
Activity pressure 0.01; No reversal markers Next-Week ExpectancyNegative 43.59%Next-week expectancy is negative with a 43.59% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors20/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 94; Small Cap Core rank 71 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Options35/100NNOX shows volatility options pressure with a 52/100 conviction score, put-call volume ratio of 0.06, expected move of 31.0%, and Sharemaestro trend signal inactive.
Volatility · Volatility expansion watch · Expected move 31.0% Sentiment32/100Weighted news tone is negative across 54 relevant articles.
NANO-X CLASS ACTION DEADLINE AUGUST 11th: Bragar Eagel & Squire, P.C. Reminds Nano-X Imaging Ltd. Investors that a Class Action Lawsuit Has Been Filed Against Nano-X and Encourages Investors to Contact the Firm Insiders50/100No recent insider transaction evidence is stored.
Earnings13dNext report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 24 Jul 2026 | 0.90 USD | -20.0% | 2.11 USD | 5.63 USD | -1.13 | -71.70 | 4.6M | Off |
| 17 Jul 2026 | 1.12 USD | 6.7% | 2.18 USD | 5.70 USD | -0.94 | -66.31 | 5.6M | Off |
| 10 Jul 2026 | 1.05 USD | -19.2% | 2.24 USD | 5.79 USD | -0.76 | -70.62 | 6.7M | Off |
| 3 Jul 2026 | 1.30 USD | 19.3% | 2.31 USD | 5.88 USD | -0.50 | -64.05 | 14.8M | Off |
| 26 Jun 2026 | 1.09 USD | -34.7% | 2.39 USD | 5.96 USD | -0.27 | -70.47 | 52.5M | Off |
| 19 Jun 2026 | 1.67 USD | -5.1% | 2.50 USD | 6.05 USD | -0.10 | -58.03 | 3.7M | Off |
| 12 Jun 2026 | 1.76 USD | -8.8% | 2.59 USD | 6.14 USD | -0.05 | -55.74 | 5.2M | Off |
| 5 Jun 2026 | 1.93 USD | 0.5% | 2.63 USD | 6.25 USD | -0.07 | -51.55 | 6.4M | Off |
| 29 May 2026 | 1.92 USD | 4.3% | 2.67 USD | 6.36 USD | -0.25 | -55.15 | 5.8M | Off |
| 22 May 2026 | 1.84 USD | 7.0% | 2.73 USD | 6.48 USD | -0.37 | -56.82 | 5.8M | Off |
| 15 May 2026 | 1.72 USD | -0.6% | 2.80 USD | 6.58 USD | -0.35 | -60.12 | 7.1M | Off |
| 8 May 2026 | 1.73 USD | 0.0% | 2.88 USD | 6.69 USD | 0.06 | -61.05 | 5.8M | Off |
| 1 May 2026 | 1.73 USD | -0.3% | 2.95 USD | 6.80 USD | 0.16 | -59.94 | 9.1M | Off |
| 24 Apr 2026 | 1.74 USD | -39.1% | 3.02 USD | 6.89 USD | 0.32 | -60.16 | 23.7M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.